HIV Therapeutics Market Outlook (2026–2030): Growth Drivers
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Is The Market Size Of The Human Immunodeficiency Virus Therapeutics Market Expected To Change From 2026 To 2030?
The human immunodeficiency virus therapeutics market size has exhibited robust growth over recent years. It is projected to expand from $14.9 billion in 2025 to $15.73 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.6%. This historical growth can be attributed to the global burden of HIV infections, the widespread adoption of antiretroviral therapy, government-funded HIV treatment programs, the increasing availability of generic HIV drugs, and improved survival rates among HIV patients.
The human immunodeficiency virus therapeutics market is anticipated to experience substantial expansion in the coming years. Its value is projected to reach $19.4 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.4%. This anticipated growth during the forecast period is driven by several factors, including a heightened demand for long-acting HIV therapeutics, a stronger emphasis on individualized HIV treatment plans, broader availability of HIV treatment in lower and middle-income nations, increased funding for advanced antiretroviral medications, and a greater commitment to continuous HIV disease management throughout life. Key trends expected within this period involve the wider uptake of combination antiretroviral therapies, a growing preference for long-acting injectable HIV treatments, an intensified focus on achieving early and lasting viral suppression, an increase in the availability of generic antiretroviral drugs, and a heightened importance placed on treatment compliance and streamlined therapeutic approaches.
Access Your Free Sample Report For In-Depth Market Analysis:
Which Factors Are Influencing The Growth Of The Human Immunodeficiency Virus Therapeutics Market?
The increasing frequency of unprotected sexual encounters is anticipated to drive the expansion of the human immunodeficiency virus therapeutics market in the future. These practices involve sexual activities conducted without barrier protection, consequently elevating the danger of sexually transmitted infections (STIs) and unplanned pregnancies. A deficiency in thorough sex education contributes to insufficient knowledge concerning safe practices, thereby promoting higher-risk behaviors, particularly among young individuals. Human immunodeficiency virus therapeutics play a role in mitigating the potential for HIV transmission arising from unprotected sexual activities by effectively lowering viral load to undetectable concentrations, thus halting the continued dissemination of the infection. As an illustration, data from November 2024, released by the Centers for Disease Control and Prevention, a US-based government agency, indicated that a 2023 survey of U.S. high school students revealed 32% had engaged in sexual intercourse at least once, and 48% confirmed not using a condom during their most recent sexual encounter. Consequently, the rising occurrence of unprotected sexual practices is fueling the expansion of the human immunodeficiency virus therapeutics market.
What Are The Main Segments Within The Human Immunodeficiency Virus Therapeutics Market Segment Structure?
The human immunodeficiency virus therapeutics market covered in this report is segmented –
1) By Drug Type: Branded Drugs, Generic Drugs
2) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
3) By End-user: Hospitals And Clinics, Specialty Centers
Subsegments:
1) By Branded Drugs: Biktarvy, Triumeq, Genvoya, Juluca, Dovato, Isentress, Prezista
2) By Generic Drugs: Tenofovir Disoproxil Fumarate (TDF), Lamivudine, Efavirenz, Zidovudine, Nevirapine, Abacavir, Ritonavir
Which Trends Are Influencing Demand In The Human Immunodeficiency Virus Therapeutics Market?
Leading companies in the Human Immunodeficiency Virus Therapeutics market are concentrating on developing long-acting, highly effective prevention and treatment options, broadening access through supportive reimbursement initiatives, and advancing innovative clinical strategies to improve adherence and reduce new HIV infections. For example, in June 2025, Gilead Sciences, a US-based healthcare company, obtained FDA approval for Yeztugo (lenacapavir), which is the first and only twice-yearly injectable PrEP option, representing a significant breakthrough in HIV prevention. Supported by Phase 3 PURPOSE 1 and PURPOSE 2 data, the drug exhibited exceptional efficacy, with =99.9% of participants remaining HIV-negative. This long-acting injection aims to mitigate challenges such as adherence difficulties, stigma, and limited awareness that restrict current PrEP usage. Yeztugo’s approval presents a promising resource to help decrease new HIV infections across varied populations. Gilead is also implementing extensive access measures, including collaborations with insurance companies, co-pay assistance for eligible patients, and free access for uninsured individuals through aid programs.
Who Are The Companies Participating In The Human Immunodeficiency Virus Therapeutics Market?
Major companies operating in the human immunodeficiency virus therapeutics market are Gilead Sciences Inc., GlaxoSmithKline plc, Merck & Co. Inc., AbbVie Inc., Johnson & Johnson, Bristol Myers Squibb Company, Pfizer Inc., F Hoffmann La Roche Ltd., Sanofi SA, Novartis International AG, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Cipla Limited, Aurobindo Pharma Limited, Hetero Labs Limited, Viatris Inc., Sun Pharmaceutical Industries Ltd., Lupin Limited, Dr Reddy’s Laboratories Ltd., Mylan N.V.
Get The Full Human Immunodeficiency Virus Therapeutics Market Report:
Where Is The Human Immunodeficiency Virus Therapeutics Market Primarily Concentrated By Region?
North America was the largest region in the human immunodeficiency virus therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human immunodeficiency virus therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Human Immunodeficiency Virus Therapeutics Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Human Immunodeficiency Virus Therapeutics Market 2026, By The Business Research Company
Human Immunodeficiency Virus Hiv Diagnosis Market Report 2026
Antiviral Combination Therapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/antiviral-combination-therapy-global-market-report
Infectious Disease Therapeutics Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
